Abbreviations/Acronyms: AMD = age-related macular degeneration; CNV = choroidal neovascularization; EMR = electronic medical record; ETDRS = Early Treatment Diabetic Retinopathy Study; FFA = fundus fluorescein angiography; GA = geographic atrophy; ICD = International Classification of Diseases; IOP = intraocular pressure; IQR = interquartile range; nAMD = neovascular age-related macular degeneration; NHS = National Health Service; OCT = optical coherence tomography; SD = standard deviation; VA = visual acuity; VEGF = vascular endothelial growth factor.
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Abstract (350/350 words)
Objective: To estimate the direct ophthalmic health care resource use in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Design: Retrospective analysis of anonymized data derived from electronic medical records acquired at 10 clinical sites in the United Kingdom. Intravitreal treatment costs in the GA : CNV group were excluded.
Participants
Results: For all 3 GA subgroups (n = 1080), the median number of visits over the first 2 years was 5 and monitoring costs were £460.80 per patient. The GA : CNV subgroup (n = 355) had the highest number of visits (median, 15) , with a cost of £1581, compared with the GA : E subgroup (n = 283; median 4 visits; cost ~£369) and the GA : GA subgroup (n = 442; median 3 visits; cost ~£277).
Ophthalmic tests were conducted most frequently in the GA : CNV subgroup. Visits and costs in the E : E subgroup (n = 6079) were lower.
Conclusions:
Resource use in patients with GA varies considerably and is strongly influenced by the concomitant presence of CNV and lack of monitoring strategies for GA.
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Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) affects >5 million people worldwide and is associated with profound visual dysfunction and irreversible vision loss as the disease progresses. 1, 2 This currently untreatable disease interferes with everyday activities (such as reading and seeing in low-light conditions) and negatively impacts quality of life. 2, 3 Realworld information on the functional impact and ophthalmic resource use in GA is limited. 4, 5 We have shown through analysis of a multicenter UK electronic medical record (EMR) database that patients with bilateral GA (n = 1901) experience high degrees of visual impairment at levels that impede mobility and affect independence. 6 In this study, 7% of patients were eligible for UK blindness registration based on visual acuity (VA) in the better-seeing eye at initial GA diagnosis, and 71% of patients had a VA that in the better-seeing eye would have rendered them ineligible to drive. 6 A further reduction in VA over the subsequent 2 years in better eyes to <70 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters resulted in an additional two-thirds of patients becoming ineligible to drive (UK driving standard: Snellen binocular 6/12; US Snellen binocular 20/40).
Notably, one-sixth of the included population had a decline in VA to <20 ETDRS letters in the betterseeing eye, thus becoming eligible for blindness registration (UK blindness definition: Snellen 3/60; US Snellen 20/400). 6 The rate of progression from GA to choroidal neovascularization (CNV) in either eye was ~7% per patient-year. 6 These data reveal the inexorable progression of vision loss in GA, its strong association with CNV, and a lack of therapies for prevention of progression or amelioration of this condition. Thus, there is a high burden of disease and it will have an associated economic cost to patients, caregivers, and health care providers.
Although the economic burden of advanced AMD has been described in the literature, the majority of studies do not differentiate between GA and neovascular AMD (nAMD), which is characterized by the presence of CNV, or report data derived solely from patients with nAMD. [7] [8] [9] [10] [11] Two studies that included both types of advanced AMD reported that resource use costs were more than twice as high for nAMD compared with GA: a large US Medicare population (years 1999-2001), 9 and a smaller study from Italy (based on data from 1998 and 1999). 10 Because the last 2 decades have seen marked changes in the monitoring of patients with AMD as novel noninvasive M A N U S C R I P T 
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Methods
Study Design
The study design has been fully described elsewhere. 6 Briefly, data collected from 10 NHS clinical sites in the United Kingdom using Medisoft (MediSoft Limited, Leeds, UK), 12 an electronic medical information capture platform, were amalgamated to construct an anonymized, retrospective Selection criteria for the full cohort of patient data extracted from the UK EMR database has been described previously. 6 Briefly, patients were aged ≥50 years, and patients in the GA subgroups had diagnosis. This cutoff date was used so that costs would reflect current practice, particularly that relating to the wider availability and use of spectral-domain optical coherence tomography (OCT).
A study eye and fellow eye were designated for each patient. In patients with bilateral GA (GA : GA) or bilateral early/intermediate AMD (E : E) the eye with the worse VA was designated as the study eye. If both eyes met inclusion criteria and had the same VA, the right eye was designated as the study eye. In patients with GA in only 1 eye at index date, the eye with GA was designated the study eye and the fellow eye was the eye with nAMD (designated as CNV in this study; i.e., GA :
CNV) or early/intermediate AMD (GA : E). Important findings from prior analyses of this dataset, including mean change in VA over time, progression to CNV, progression to loss of ≥10 or ≥15
ETDRS letters, progression to blindness, and progression to loss of driving eligibility for the GA : GA subgroup, have been published previously. (Table 1) .
Direct Ophthalmology-Related Visits and Costs
In the 1080 patients with GA in ≥1 eye, the median (IQR) number of visits in the first 2 years of (Fig 1) . These costs were lower than those for any of the GA subgroups.
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Ocular-Related Tests
The types of monitoring tests recorded for the 4 subgroups over the first 2 years are shown in 
Discussion
Because direct ophthalmic health care resource utilization data among patients with GA in clinical practice are limited, we sought to address this knowledge gap by using a large EMR database to calculate direct ophthalmology-related costs in a large cohort of patients who were attenders in 10 clinical sites in the United Kingdom. We calculated that the median (IQR) cost of monitoring patients with GA only in 1 or both eyes was £460.80 (£206.7-1068.3) over 2 years of follow-up following diagnosis. We observed, however, that there was no consistent pattern of care in patients diagnosed with GA only in 1 or both eyes. Our data showed that the number of visits and associated costs among patients with GA with CNV in their fellow eye (GA : CNV) was ~4-5 times higher than those in the GA : GA and GA : E categories. We also calculated the direct monitoring costs associated with a diagnosis of early/intermediate AMD in both eyes, and observed these to be lower than for patients with GA, with a median of only 2 associated visits over the first 2 years following diagnosis.
The economic burden associated with GA in the published literature is scarce, possibly because of inconsistencies with respect to GA diagnosis due to the use of differing grading systems and imaging modalities resulting in variation in terminology, 15 or because GA was only recently granted a diagnosis code (9B75.02) by the World Health Organization. 16 Also, the lack of any M A N U S C R I P T
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Italy between 1998 and 1999, resource utilization and direct medical costs were evaluated in 476 patients aged ≥50 years with diagnoses of any AMD, and with follow-up for 1 year. The majority of the patients included in the study had CNV (n = 285; 59.9% of the study population), and a smaller proportion (n = 113; 23.7%) had early AMD, defined as those with drusen. Those with GA were the smallest group in the study, and accounted for fewer than one-fifth (n = 78; 16.4%) of the entire sample. 10 The mean cost per patient per year was highest in patients with CNV and lowest in those diagnosed with GA, while services directly paid for by patients were highest for patients with GA and lowest for those with CNV. 10 On comparing the GA subgroup in the Italian study (95% of whom had bilateral disease) with ours, we observed that the mean cost calculated over 1 year (excluding hospitalization costs and private expenditure, which were not captured by our analysis) was similar to that of our study after accounting for the longer duration of follow-up. Thus, despite the passage of over 2 decades since the Italian study, the costs remain similar, indicating minimal change in clinical monitoring practice in the GA-only group. By contrast, the monitoring costs for the GA : CNV group were much higher in our study compared with the Italian study and almost certainly relate to the availability of anti-vascular endothelial growth factor (VEGF) treatments for nAMD, which necessitate more frequent monitoring. These patients were seen more often and their eyes with GA monitored because of their fellow eye diagnosis of CNV, the treatment of which would drive visits for follow-up monitoring. The lower health care resource use reported for managing GA compared with CNV most likely reflects the lack of an effective drug treatment for GA and a lack of recognition that GA may be a precursor to CNV. In fact, because the number of patients with glaucoma in the GA :
GA and GA : E groups were higher than in the GA : CNV group, it is possible that monitoring of these former groups was occurring mainly for non-AMD-related pathology. In addition, some of the patients in all the groups and in all the centers may have had cataract or other ocular surgery, or M A N U S C R I P T
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We also compared the results of our study with that of an analysis of US Medicare claims data from 1999-2001, which used the International Classification of Diseases (ICD), Ninth Revision, Clinical Modification diagnosis codes to classify patients. We assumed that the group classified as dry AMD in the US study had GA because there was a subclassification of drusen only. The annual rate of ophthalmic resource utilization and cost per patient in the GA group was similar to that of ours. 9 The mean annual cost in the "wet AMD" group in the US Medicare claims had been calculated for visits, diagnostic procedures, therapeutic interventions, and physician consultations.
In our study, costs arising from therapeutic interventions were not included the costing model.
Therefore, on comparing the costs in the US Medicare study for the subgroup labeled "wet and dry,"
with therapeutic interventions excluded, with those in our study, we observed a >2-fold increase in the median costs in our GA : CNV group, albeit over the first 2 years. Again, the increase in costs reflects the increased need for monitoring of patients managed with anti-VEGF therapies. 9 Future research could make use of the ICD 11th Revision coding on GA to facilitate a better understanding of resource use around this form of AMD.
We also considered the potential impact of our EMR database studies on both policy and guidance that is widely available in the literature. 17, 18 That GA is often a precursor to CNV, with a progression rate of 4.8% per patient year in patients with bilateral GA, 6 suggests that vigilance should be employed in terms of both advice and follow up for patients who present with unilateral or bilateral GA. While repeated review at short intervals is unlikely to be beneficial as the exudative manifestations of CNV can appear suddenly and dramatically, information should be provided on the risk estimates and the symptoms that would alert the patient to the onset of CNV. Additionally, the data on progression rates will prove useful for future health economic analysis on the value of devices that can be used for home monitoring to detect onset of CNV. Our findings also add emphasis to existing guidance on giving advice to patients with GA or early/intermediate AMD. The present study has several strengths. Firstly, the data represent the largest cohort of patients with GA managed in a routine clinical setting with a minimum follow-up for 2 years.
Secondly, the disease definitions (i.e., GA, CNV, and early/intermediate AMD) were validated and found to be accurate in a large random selection of patients in this dataset with high positive and negative predictive values for progression to CNV. 6 Thirdly, data on VA, IOP, and OCT are recorded in dropdown fields and captured in the EMR system with high fidelity.
This work has a number of limitations. Firstly, key among the limitations is that the EMR there are no approved treatments for GA, and follow-up of GA is unlikely, particularly for services with capacity issues. To date, the only intervention that has some benefit in the early nonneovascular stages of AMD is the Age-Related Eye Disease Study (AREDS) formulation (a nutritional supplement containing vitamin C, vitamin E, beta-carotene, zinc and copper; later modified to exclude beta-carotene and include lutein and zeaxanthin on the basis of the AREDS2 study) 19, 20 , but even this was not shown to retard the progression to GA. 19 Finally, a further limitation of our study is its focus on direct resource utilization within the chosen clinical sites in a single country. However, we believe that clinical practice in the monitoring of early AMD and GA is similar across most developed economies. Neither direct treatment costs (e.g., anti-VEGF injection or antioxidant vitamins and minerals [as used in the AREDS 19, 20 ]) nor indirect costs (e.g., vision-related M A N U S C R I P T
UK EMR HCRU manuscript Journal: Ophthalmology Retina 13 hospital admissions, caregiver costs, lost income, vision aids) were included in this analysis. Finally, we did not employ a micro-costing approach in each of the centers but relied instead on the use of published NHS costs for visits and procedures, which may underestimate the true costs of monitoring incurred by the centers.
In conclusion, direct ophthalmic health care resource use costs estimated using a large clinical dataset revealed a modest cost over a 2-year period in patients with GA in 1 or both eyes.
However, the prevalence of GA in the United Kingdom was estimated in 2012 at 276,000 and was projected to rise over the next decade. 21 Based on the prevalence of GA in 2012, the cost of monitoring-only eye care services over a 2-year period is likely to be of the order of £127 million.
With promising therapies being tested in the prevention of progression from early AMD to GA and even from early GA to more advanced GA, the potential cost of managing this condition is likely to escalate dramatically in the future. Our clinic-based data provide information for health care providers interested in the burden of illness due to GA, particularly with respect to planning and organization of resource allocation. However, there is a remaining need for additional research on the indirect costs of GA, including those related to caregiving, transportation, and lost income. We recommend ICD 11th Revision coding for GA to be used uniformly across the nations for better understanding of resource utilization in managing these patients. 
